home > news > detailed info

PCI Pharma Services announces Eric Anderson as newest Business Development Executive to join the North American commercial packaging team.

PCI Pharma Services

Philadelphia, PA, 21 August 2017

PCI is pleased to announce the addition of Eric Anderson in the role of Account Executive, supporting the growth and success of PCI’s well-established Commercial Packaging business. Eric will be responsible for account management and territory growth for the company’s commercial packaging services in the East Coast, maintaining and growing market share with key customers while developing new business.

Eric brings with him an extensive career in technical development roles, having started his career at Anderson Packaging and later at PCI, where he gained experience in packaging design and development, planning and project management roles, as well as subsequent roles at specialty pharmaceutical company TOLMAR in package engineering and development.

Commenting on his appointment, Phil DiGiacomo, Senior Vice President of Business Development, said: “We are delighted to welcome back Eric to PCI. He brings a wealth of experience in packaging and will be using this technical knowledge to help support customers as they look to bring new medicines to market. His background will be invaluable and we are looking forward to Eric’s insights and experience to significantly benefit our clients.”

Eric stated: “I’m excited to be back at PCI and part of a team that is dedicated to serving clients with innovative packaging solutions and ongoing investment in capacity expansions to meet business growth. I am looking forward to applying my previous experiences to the responsibilities of my new role, focusing on providing customers the industry leading experience.”

Prior to re-joining PCI, Eric worked as Project Lead at TOLMAR for packaging development activities for various specialty injectable and dermatological applications. Eric is a graduate of the Michigan State University School of Packaging.

Eric joins PCI at a time of significant investment in its commercial packaging business over the past year, including capacity expansions of its packaging equipment including multiple bottling lines, as well as a recent investment of market leading Serialization capability that will effectively triple its Serialization capacity. The multi-site installations support a variety of drug delivery forms, including bottles, unit cartons and parenteral kits, as well as unit dose wallets and child resistant/compliance prompting packaging.

About PCI

The global healthcare industry trusts PCI for the drug development solutions that increase their products’ speed to market and opportunities for commercial success. Only PCI brings the proven experience that comes with more than 50 successful product launches a year and over four decades in the healthcare business. Leading technology and continued investment enables us to address global development needs throughout the product life cycle — from Phase I clinical trials through commercialization and ongoing supply. Our clients view us as an extension of their business and a collaborative partner, with the shared goal of improving patients’ lives. For more information, please visit or follow us on Twitter at  @PCI_Social.


Chantel Richman/Carrie Lowe at Remarkable Content /
T +44 (0) 1962 893 853/913
phone +44 (0)1495 713 633
email Wye Valley Business Park, Hay-on-Wye, HR3 5PG
Print this page
Send to a friend
News and Press Releases

HATRIC-based identification of receptors for orphan ligands (small molecules)

HATRIC-LRC (Ligand Receptor Capture) enables now the identification of small molecule targets on the surface of living cells! Even primary cells!
More info >>

White Papers

Clinical Trials in Russia Orange Paper: 1st Quarter 2014

Synergy Research Group

In summary, Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia: 1. Fast patient enrollment due to the centralized medical infrastructure. 2. Nearly 100% patient retention 3. GCP trained and certified Investigative Sites generating high quality data 4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >>

Industry Events

SMi’s 5th Molecular Diagnostics Conference

9-11 July 2018, Holiday Inn Kensington Forum, London, UK

SMi is proud to announce their 5th Molecular Diagnostics conference. The event will take place in central London on Monday 9th and Tuesday 10th July 2018, along with two half-day post-conference workshops taking place on Wednesday 11th July 2018
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement